Abstract P046: ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)

Mapping Intimacies ◽

10.1158/1535-7163.targ-21-p046 ◽

2021 ◽

Author(s):

Susana N. Banerjee ◽

Bradley J. Monk ◽

Els Van Nieuwenhuysen ◽

Kathleen N. Moore ◽

Ana Oaknin ◽

...

Keyword(s):

Ovarian Cancer ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Phase 2 ◽

Phase 2 Study

Download Full-text

Abstract B23: CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines

10.1158/1557-3265.ovca19-b23 ◽

2020 ◽

Author(s):

Joshua Hoenisch ◽

Hannah Kim ◽

Amy Dawson ◽

Nicole Lam ◽

Dane A. Cheasley ◽

...

Keyword(s):

Ovarian Cancer ◽

Cell Lines ◽

Cancer Cell ◽

Ovarian Cancer Cell ◽

Mek Inhibitor ◽

Cancer Cell Lines ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Ovarian Cancer Cell Lines ◽

Inhibitor Combination

Download Full-text

The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps5618 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS5618-TPS5618

Author(s):

Bradley J. Monk ◽

Rachel N. Grisham ◽

Christian Marth ◽

Susana N. Banerjee ◽

Felix Hilpert ◽

...

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps5610 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS5610-TPS5610 ◽

Cited By ~ 4

Author(s):

Bradley J. Monk ◽

Rachel N. Grisham ◽

Christian Marth ◽

Susana N. Banerjee ◽

Felix Hilpert ◽

...

Keyword(s):

Ovarian Cancer ◽

Fallopian Tube ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1168 ◽

2021 ◽

Vol 32 ◽

pp. S728

Author(s):

S. Banerjee ◽

R. Grochot ◽

R. Shinde ◽

J. Lima ◽

M. Krebs ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Study ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer

Download Full-text

Abstract A48: Anti-tumor activity of the MEK inhibitor pimasertib in combination with the PI3K/mTOR inhibitor SAR245409 in low-grade serous ovarian cancer

10.1158/1078-0432.ovca13-a48 ◽

2013 ◽

Author(s):

Sukhvinder S. Sidhu ◽

Frank Campana ◽

Coumaran Egile ◽

Karl Hsu ◽

Samantha Goodstal ◽

...

Keyword(s):

Ovarian Cancer ◽

Mtor Inhibitor ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Anti Tumor Activity

Download Full-text

Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.05.019 ◽

2017 ◽

Vol 146 (2) ◽

pp. 319-326 ◽

Cited By ~ 12

Author(s):

Ismail Mert ◽

Jasdeep Chhina ◽

Ghassan Allo ◽

Jing Dai ◽

Shelly Seward ◽

...

Keyword(s):

Ovarian Cancer ◽

Synergistic Effect ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer

Download Full-text

O9-1 Updated results of a phase 2 study of niraparib in heavily pretreated high-grade serous ovarian cancer patients in Japan

Annals of Oncology ◽

10.1016/j.annonc.2021.05.533 ◽

2021 ◽

Vol 32 ◽

pp. S288

Author(s):

Kazuhiro Takehara ◽

Eiji Kondo ◽

Satoshi Yanagida ◽

Toshiaki Nakamura ◽

Junzou Hamanishi ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

High Grade ◽

Serous Ovarian Cancer ◽

Phase 2 ◽

Phase 2 Study ◽

Heavily Pretreated

Download Full-text

Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient

Molecular Case Studies ◽

10.1101/mcs.a004341 ◽

2019 ◽

Vol 5 (6) ◽

pp. a004341 ◽

Cited By ~ 2

Author(s):

Ilaria Colombo ◽

Swati Garg ◽

Arnavaz Danesh ◽

Jeffrey Bruce ◽

Patricia Shaw ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patient ◽

Ovarian Cancer Patient ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Inhibitor Resistance

Download Full-text

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

Cancer Cell International ◽

10.1186/s12935-019-0725-1 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 12

Author(s):

Marta Llaurado Fernandez ◽

Amy Dawson ◽

Joshua Hoenisch ◽

Hannah Kim ◽

Sylvia Bamford ◽

...

Keyword(s):

Ovarian Cancer ◽

Therapeutic Target ◽

Mek Inhibitor ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Potential Therapeutic Target ◽

Inhibitor Resistance

Download Full-text

Faculty Opinions recommendation of Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8266958.8697057 ◽

2011 ◽

Author(s):

Ashley Stuckey

Keyword(s):

Ovarian Cancer ◽

Low Grade ◽

Serous Ovarian Cancer ◽

Breast And Ovarian Cancer ◽

Tumor Spectrum

Download Full-text